Open Access

Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head

  • Authors:
    • Zhen‑Hong Zhu
    • Wen‑Qi Song
    • Chang‑Qing Zhang
    • Ji‑Min Yin
  • View Affiliations

  • Published online on: September 13, 2016     https://doi.org/10.3892/etm.2016.3698
  • Pages: 2843-2850
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mesenchymal stem cells have been widely studied to promote local bone regeneration of osteonecrosis of the femoral head (ONFH). Previous studies observed that dimethyloxaloylglycine (DMOG) enhanced the angiogenic and osteogenic activity of mesenchymal stem cells by activating the expression of hypoxia inducible factor‑1α (HIF‑1α), thereby improving the bone repair capacity of mesenchymal stem cells. In the present study, it was investigated whether DMOG could increase the bone repair capacity of adipose‑derived stem cells (ASCs) in the treatment of ONFH. Western blot analysis was performed to detect HIF‑1α protein expression in ASCs treated with different concentrations of DMOG. The results showed DMOG enhanced HIF‑1α expression in ASCs in a dose‑dependent manner at least for 7 days. Furthermore, DMOG‑treated ASCs were transplanted into the necrotic area of a rabbit model of ONFH to treat the disease. Four weeks later, micro‑computed tomography (CT) quantitative analysis showed that 58.8±7.4% of the necrotic area was regenerated in the DMOG‑treated ASCs transplantation group, 45.5±3.4% in normal ASCs transplantation group, 25.2±2.8% in only core decompression group and 10.6±2.6% in the untreated group. Histological analysis showed that transplantation of DMOG‑treated ASCs clearly improved the bone regeneration of the necrotic area compared with the other three groups. Micro‑CT and immunohistochemical analysis demonstrated the revasculation of the necrotic area were also increased significantly in the DMOG‑treated ASC group compared with the control groups. Thus, it is hypothesized that DMOG could increase the bone repair capacity of ASCs through enhancing HIF‑1α expression in the treatment of ONFH.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu ZH, Song WQ, Zhang CQ and Yin JM: Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head. Exp Ther Med 12: 2843-2850, 2016
APA
Zhu, Z., Song, W., Zhang, C., & Yin, J. (2016). Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head. Experimental and Therapeutic Medicine, 12, 2843-2850. https://doi.org/10.3892/etm.2016.3698
MLA
Zhu, Z., Song, W., Zhang, C., Yin, J."Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head". Experimental and Therapeutic Medicine 12.5 (2016): 2843-2850.
Chicago
Zhu, Z., Song, W., Zhang, C., Yin, J."Dimethyloxaloylglycine increases bone repair capacity of adipose-derived stem cells in the treatment of osteonecrosis of the femoral head". Experimental and Therapeutic Medicine 12, no. 5 (2016): 2843-2850. https://doi.org/10.3892/etm.2016.3698